NCT01622361 - Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Breast Cancer

Interventions

DRUG

Adriamycin+Cyclophosphamide>Docetaxel

"1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~ * Route: by slow intravenous bolus~ * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~ * Route: intravenous as per local practice~ * Schedule: every 3weeks for 4 cycle"

DRUG

GnRHa with Tamoxifen

"1. Goserelin(GnRHa) 3.6mg~ * Route: subcutaneously under the abdominal skin~ * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~ * Route: Oral~ * Schedule: everyday"

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul